Francis D Graziano, Uchechukwu O Amakiri, Jacob Levy, Ronnie L Shammas, Jonathan Rubin, Lillian Boe, Evan Matros, Babak J Mehrara, Robert J Allen, Jonas A Nelson
{"title":"Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction.","authors":"Francis D Graziano, Uchechukwu O Amakiri, Jacob Levy, Ronnie L Shammas, Jonathan Rubin, Lillian Boe, Evan Matros, Babak J Mehrara, Robert J Allen, Jonas A Nelson","doi":"10.1002/jso.28030","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing abdominal-based free flap breast reconstruction are at risk for perioperative venous thromboembolism (VTE), but the optimal anticoagulation protocol remains unknown. We hypothesized that a standardized chemoprophylaxis protocol would minimize VTE events without increasing hematoma, flap loss, or reoperation.</p><p><strong>Methods: </strong>A retrospective review was conducted on patients who underwent abdominal-based free flap breast reconstruction from 2010 to 2023. In 2015, we implemented an enhanced recovery after surgery (ERAS) protocol including preoperative enoxaparin. Patients with a BMI < 30 and > 30 received enoxaparin for 7 and 30 days postoperatively, respectively. 2010-2015 patients were pre-ERAS and 2015-2023 patients were the ERAS cohort. Patient demographics, comorbidities, and outcomes were analyzed. The primary outcomes were VTE, hematoma, flap loss, and reoperation.</p><p><strong>Results: </strong>2317 patients were included: 679 were pre-ERAS and 1638 were in the ERAS cohort. The incidence of deep vein thrombosis (0.7%) and pulmonary embolism (pre-ERAS 0.6% vs. ERAS 0.5%) was low in both cohorts with no significant differences. Hematoma (pre-ERAS 7.2% vs. ERAS 5.5%) and reoperation (pre-ERAS 7.8% vs. ERAS 9.7%) were similar, but the ERAS cohort had significantly lower flap failure (0.7% vs. 2.1%, p < 0.05).</p><p><strong>Conclusions: </strong>A standardized perioperative anticoagulation protocol for abdominal-based breast reconstruction maintained low VTE rates without increasing hematoma, flap failure, or reoperation.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.28030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Patients undergoing abdominal-based free flap breast reconstruction are at risk for perioperative venous thromboembolism (VTE), but the optimal anticoagulation protocol remains unknown. We hypothesized that a standardized chemoprophylaxis protocol would minimize VTE events without increasing hematoma, flap loss, or reoperation.
Methods: A retrospective review was conducted on patients who underwent abdominal-based free flap breast reconstruction from 2010 to 2023. In 2015, we implemented an enhanced recovery after surgery (ERAS) protocol including preoperative enoxaparin. Patients with a BMI < 30 and > 30 received enoxaparin for 7 and 30 days postoperatively, respectively. 2010-2015 patients were pre-ERAS and 2015-2023 patients were the ERAS cohort. Patient demographics, comorbidities, and outcomes were analyzed. The primary outcomes were VTE, hematoma, flap loss, and reoperation.
Results: 2317 patients were included: 679 were pre-ERAS and 1638 were in the ERAS cohort. The incidence of deep vein thrombosis (0.7%) and pulmonary embolism (pre-ERAS 0.6% vs. ERAS 0.5%) was low in both cohorts with no significant differences. Hematoma (pre-ERAS 7.2% vs. ERAS 5.5%) and reoperation (pre-ERAS 7.8% vs. ERAS 9.7%) were similar, but the ERAS cohort had significantly lower flap failure (0.7% vs. 2.1%, p < 0.05).
Conclusions: A standardized perioperative anticoagulation protocol for abdominal-based breast reconstruction maintained low VTE rates without increasing hematoma, flap failure, or reoperation.
背景:接受腹部自由皮瓣乳房重建的患者有围手术期静脉血栓栓塞(VTE)的风险,但最佳的抗凝方案仍然未知。我们假设标准化的化学预防方案可以在不增加血肿、皮瓣丢失或再手术的情况下减少静脉血栓栓塞事件。方法:回顾性分析2010 ~ 2023年行腹侧游离皮瓣乳房再造术的病例。2015年,我们实施了一项增强术后恢复(ERAS)方案,包括术前使用依诺肝素。BMI为30的患者分别在术后7天和30天接受依诺肝素治疗。2010-2015年患者为ERAS前患者,2015-2023年患者为ERAS队列。分析患者人口统计、合并症和结果。主要结果为静脉血栓栓塞、血肿、皮瓣丢失和再手术。结果:纳入2317例患者,其中679例为ERAS前期,1638例为ERAS队列。在两个队列中,深静脉血栓形成(0.7%)和肺栓塞(ERAS前0.6% vs ERAS 0.5%)的发生率均较低,无显著差异。血肿(ERAS前7.2% vs ERAS 5.5%)和再手术(ERAS前7.8% vs ERAS 9.7%)相似,但ERAS队列的皮瓣失败率明显较低(0.7% vs 2.1%)。结论:标准化的围手术期抗凝治疗方案用于腹部乳房重建术,在不增加血肿、皮瓣失败或再手术的情况下保持了较低的VTE率。
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.